Floatz logo

Abt-301

Optic Neuropathy

West Penn Allegheny Health SystemEarly Phase 1Dormant
C
39/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
24/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Optic Neuropathy cohort.

Asset / SponsorPhaseRating
Cnm-Au8
Clene Nanomedicine
Phase 2CCC
Tislelizumab
West Penn Allegheny Health System
Early Phase 1C

Same molecule, other indications

Abt-301 is also rated in:

Metastatic Colorectal CancerDormant
B
Indicative ·
63 / 100
View asset →
Metastatic MelanomaDormant
CCC
Indicative ·
54 / 100
View asset →
Colorectal NeoplasmsDormant
CCC
Indicative ·
54 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →